GlaxoSmithKline granted its first voluntary license in 2001. Now under the auspices of ViiV Healthcare, the number of licenses has been extended to sixteen royalty free licensing agreements for ViiV Healthcare's ARVs to all least developed countries, all low income countries and sub-Saharan Africa.
ViiV Healthcare's licensees supplied 1.1 billion tablets of their versions of Epivir® and Combivir® to Africa in 2012.
In 2014 ViiV Healthcare granted two voluntary licenses to the Medicines Patent Pool in order to expand access to their newest medicine dolutegravir, just three months after its approval by the European Medicines Agency (EMA), This agreement included a royalty-free voluntary license for manufacture and supply of dolutegravir in all low-income, all least-developed and all sub-Saharan African countries – covering over 93% of all adults living with HIV. Additionally, ViiV Healthcare also provided a royalty-free license for the development, manufacture and supply of pediatric formulations of dolutegravir in the countries where 99% of all children with HIV live.
|Location||Southern Africa, West Africa, Eastern Africa, Central Africa|